Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 213-219

  Herzig, Maryanne C S ^a   Chapman, William G ^a   Sheridan, Ann ^a   Rake, James B ^b   Woynarowski, Jan M ^a  

^a CTRC Institute for Drug Development   (United States)

^b Sanofi Research Division   (United States)

Author keywords

Calcium; Inverse agonist; MIA PaCa 2; Neurotensin; PANC 1; SR 48692

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; CALCIUM ION; NEUROPEPTIDE; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SECOND MESSENGER;

ANTINEOPLASTIC AGENTS; CALCIUM; CELL DIVISION; EGTAZIC ACID; HUMANS; NEUROTENSIN; PANCREATIC NEOPLASMS; PYRAZOLES; QUINOLINES; RECEPTORS, NEUROTENSIN; TUMOR CELLS, CULTURED;

EID: 0032942578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vincent JP: Neurotensin receptors: binding properties, transduction pathways, and structure. [Review] [71 refs]. Cellular & Molecular Neurobiology 15: 501-512, 1995.
2. Woll PJ: Neuropeptide growth factors and cancer. Br J Cancer 63: 469-475, 1991.
3. Evers BM, Bold RJ, Ehrenfried JA, Li J, Townsend CM, Jr., Klimpel GR: Characterization of functional neurotensin receptors on human lymphocytes. Surgery 116: 134-140, 1994.
4. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ: Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U.S.A. 91: 4673-4677, 1994.
5. Tallett A, Chilvers ER, MacKinnon AC, Haslett C, Sethi T: Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines. Peptides 17: 665-673, 1996.
6. Yoshinaga K, Evers BM, Izukura M, Parekh D, Uchida T, Townsend CM, Jr., Thompson JC: Neurotensin stimulates growth of colon cancer. Surg Oncol 1: 127-134, 1992.
7. Evers BM, Ishizuka J, Chung DH, Townsend CM, Jr., Thompson JC: Neurotensin expression and release in human colon cancers. Ann Surg 216: 423-430; discussion 430-421, 1992.
8. Kapuscinski M, Shulkes A, Read D, Hardy KJ: Expression of neurotensin in endocrine tumors. J Clin Endocrinol Metab 70: 100-106, 1990.
9. Meggiato T, Ferrara C, Tessari G, Plebani M, De Paoli M, Del Favero G, Naccarato R: Serum neurotensin in human pancreatic cancer. Tumori 82: 592-595, 1996.
10. Townsend CM, Jr., Bold RJ, Ishizuka J: Gastrointestinal hormones and cell proliferation. Surgery Today 24: 772-777, 1994.
11. Ishizuka J, Townsend CM, Jr., Thompson JC: Neurotensin regulates growth of human pancreatic cancer. Annals of Surgery 217: 439-445; discussion 446, 1993.
12. Brunt LM, Mazoujian G, TM OD, Wells SA, Jr.: Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome. Surgery 115: 362-369, 1994.
13. Yamada M, Ohata H, Momose K, Yamada M, Richelson E: Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Research Communications in Molecular Pathology & Pharmacology 90: 37-47, 1995.
14. Sumi S, Evers BM, Townsend CM, Jr., Yoshinaga K, Uchida T, Murakami M, Sato K, Ishizuka J, Thompson JC: Comparative effects of neurotensin and neuromedin N on growth of human pancreatic cancer, MIA PaCa-2. Surg Oncol 2: 267-272, 1993.
15. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A, et al.: Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U.S.A. 90: 65-69, 1993.
16. Oury-Donat F, Thurneyssen O, Gonalons N, Forgez P, Gully D, Le Fur G, Soubrie P: Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells. British Journal of Pharmacology 116: 1899-1905, 1995.
17. 3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Molecular Pharmacology 47: 1050-1056, 1995.
18. Seethalakshmi L, Mitra SP, Dohner PR, Menon M, Carraway RE: Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 31: 183-192, 1997.
19. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, Townsend CM, Jr.: Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surgical Oncology 5: 245-251, 1996.
20. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, Thompson JC, Townsend CM, Jr.: Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 79: 1787-1793, 1997.
21. Tatsuta M, Iishi H, Baba M, Nakaizumi A: Inhibition by neurotensin of azaserine-induced carcinogenesis in rat pancreas. Int J Cancer 47: 408-412, 1991.
22. 2+ Indicators with greatly Improved Fluorescence Properties. J Biol Chem 260: 3440-3450, 1985.
23. Loveland BE, Johns TG, Mackay IR, Vaillant F, Wang ZX, Hertzog PJ: Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochemistry International 27: 501-510, 1992.
24. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP: Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proceedings of the National Academy of Sciences of the United States of America 87: 2466-2470, 1990.
25. Ely JA, Ambroz C, Baukal AJ, Christensen SB, Balla T, Catt KJ: Relationship between agonist-and thapsigargin-sensitive calcium pools in adrenal glomerulosa cells. Thapsigargin-induccd Ca2+ mobilization and entry. Journal of Biological Chemistry 266: 18635-18641, 1991.
26. Shoback D, Chen TH, Pratt S, Lattyak B: Thapsigargin stimulates intracellular calcium mobilization and inhibits parathyroid hormone release. Journal of Bone & Mineral Research 10: 743-750, 1995.
27. Milligan G, Bond RA: Inverse agonism and the regulation of receptor number. [Review] [58 refs]. Trends in Pharmacological Sciences 18: 468-474, 1997.
28. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF et al: Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor [see comments]. Comment in: Nature 1995 Mar 16:374(6519):214. Nature 374: 272-276, 1995.
29. Leeb-Lundberg LM, Mathis SA, Herzig MC: Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. Journal of Biological Chemistry 269: 25970-25973, 1994.
30. Braestrup C, Nielsen M, Honore T, Jensen LH, Petersen EN: Benzodiazepine receptor ligands with positive and negative efficacy. [Review] [52 refs]. Neuropharmacology 22: 1451-1457, 1983.